251 related articles for article (PubMed ID: 8086567)
1. Erythromycin-induced QT prolongation and polymorphic ventricular tachycardia (torsades de pointes): case report and review.
Brandriss MW; Richardson WS; Barold SS
Clin Infect Dis; 1994 Jun; 18(6):995-8. PubMed ID: 8086567
[TBL] [Abstract][Full Text] [Related]
2. QT prolongation and development of torsades de pointes with the concomitant administration of oral erythromycin base and quinidine.
Lin JC; Quasny HA
Pharmacotherapy; 1997; 17(3):626-30. PubMed ID: 9165570
[TBL] [Abstract][Full Text] [Related]
3. Erythromycin induced Torsades de Pointes: case report and review of the literature.
Rezkalla MA; Pochop C
S D J Med; 1994 May; 47(5):161-4. PubMed ID: 8047870
[TBL] [Abstract][Full Text] [Related]
4. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
Oberg KC; Bauman JL
Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced torsades de pointes in one patient with congenital long QT syndrome.
Hsieh MH; Chen SA; Chiang CE; Tai CT; Lee SH; Wen ZC; Chang MS
Int J Cardiol; 1996 Apr; 54(1):85-8. PubMed ID: 8792191
[TBL] [Abstract][Full Text] [Related]
6. Erythromycin-induced torsades de pointes and ventricular fibrillation in a patient with Legionella pneumonia.
de Koning J; van der Hoeven H; Hamer B; Thompson J
Neth J Med; 1994 Apr; 44(4):131-5. PubMed ID: 8196823
[TBL] [Abstract][Full Text] [Related]
7. A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.
Katapadi K; Kostandy G; Katapadi M; Hussain KM; Schifter D
Angiology; 1997 Sep; 48(9):821-6. PubMed ID: 9313632
[TBL] [Abstract][Full Text] [Related]
8. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
9. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
Isbister GK; Balit CR; Macleod D; Duffull SB
J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient.
Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T
Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302
[TBL] [Abstract][Full Text] [Related]
11. [Erythrocyte-induced "torsade de pointes" ventricular tachycardia].
Lengyel C; Várkonyi T; Fazekas T
Orv Hetil; 1997 Apr; 138(16):1003-6. PubMed ID: 9153994
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
13. Torsades de pointes with methadone.
Prescrire Int; 2005 Apr; 14(76):61-2. PubMed ID: 15875343
[TBL] [Abstract][Full Text] [Related]
14. Cardiac arrest and electrical storm due to recurrent torsades de pointes caused by concomitant clarithromycin, cotrimoxazole and amiodarone treatment.
Bienias P; Ciurzyński M; Paczyńska M; Pruszczyk P
Pol Merkur Lekarski; 2014 Nov; 37(221):285-8. PubMed ID: 25546990
[TBL] [Abstract][Full Text] [Related]
15. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
[TBL] [Abstract][Full Text] [Related]
16. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
Antzelevitch C; Sun ZQ; Zhang ZQ; Yan GX
J Am Coll Cardiol; 1996 Dec; 28(7):1836-48. PubMed ID: 8962574
[TBL] [Abstract][Full Text] [Related]
17. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for treating cardiac manifestations of organophosphates poisoning with special emphasis on long QT and Torsades De Pointes.
Bar-Meir E; Schein O; Eisenkraft A; Rubinshtein R; Grubstein A; Militianu A; Glikson M;
Crit Rev Toxicol; 2007 Mar; 37(3):279-85. PubMed ID: 17453935
[TBL] [Abstract][Full Text] [Related]
19. Erythromycin induced torsades de pointes.
Wong CB; Windle J
Nebr Med J; 1995 Sep; 80(9):285-6. PubMed ID: 7566254
[TBL] [Abstract][Full Text] [Related]
20. Understanding drug-induced torsades de pointes: a genetic stance.
Kannankeril PJ
Expert Opin Drug Saf; 2008 May; 7(3):231-9. PubMed ID: 18462182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
